[1] Ciarapica R, Russo G, Verginelli F, et al. Deregulated expression of miR-26a and Ezh2 in rhabdomyosarcoma[J]. Cell Cycle, 2009,8(1):172-175.[2] Kota J, Chivukula R R, O'Donnell K A, et al. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model[J]. Cell, 2009,137(6):1005-1017.[3] Chau B N, Wang J Y. Coordinated regulation of life and death by RB[J]. Nat Rev Cancer, 2003,3(2):130-138.[4] Kanoe H, Nakayama T, Murakami H, et al. Amplification of the CDK4 gene in sarcomas: tumor specificity and relationship with the RB gene mutation[J]. Anticancer Res, 1998,18(4A):2317-2321.[5] Horowitz J M, Park S H, Bogenmann E, et al. Frequent inactivation of the retinoblastoma anti-oncogene is restricted to a subset of human tumor cells[J]. PNAS, 1990,87(7):2775-2779.[6] Kim H, Hang W, Jiang X L, et al. Integrative genome analysis reveals an oncomir/oncogene cluster regulating lioblastoma Survivorship[J]. PNAS, 2010,107(5):2183-2188.[7] Zhang Y F, Zhang A R, Zhang B C, et al. miR-26a regulates cell cycle and anoikis of human esophageal adenocarcinoma cells through Rb1-E2F1 signaling pathway[J]. Mol Biol Rep, 2013,40(2):1711-1720.[8] 范龙坤,华泽权,金岩,等.miR-26a对小鼠骨髓间充质干细胞成骨分化能力的调控作用[J].中国医科大学学报,2012,41(7):591-596. |